79 related articles for article (PubMed ID: 23887292)
1. CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response.
Seiler R; Thalmann GN; Rotzer D; Perren A; Fleischmann A
Mod Pathol; 2014 Jan; 27(1):87-95. PubMed ID: 23887292
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.
Stahl P; Seeschaaf C; Lebok P; Kutup A; Bockhorn M; Izbicki JR; Bokemeyer C; Simon R; Sauter G; Marx AH
BMC Gastroenterol; 2015 Feb; 15():7. PubMed ID: 25649416
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of CCND1 amplification/overexpression in smoking patients with esophageal squamous cell carcinoma.
Jiang D; Song Q; Zhang F; Xu C; Li X; Zeng H; Su J; Huang J; Xu Y; Lu S; Hou Y
Cancer Genet; 2023 Nov; 278-279():1-8. PubMed ID: 37556965
[TBL] [Abstract][Full Text] [Related]
4. CCND1 Amplification in Breast Cancer -associations With Proliferation, Histopathological Grade, Molecular Subtype and Prognosis.
Valla M; Klæstad E; Ytterhus B; Bofin AM
J Mammary Gland Biol Neoplasia; 2022 Mar; 27(1):67-77. PubMed ID: 35459982
[TBL] [Abstract][Full Text] [Related]
5. The relationship of CyclinD1 and estrogen receptor expression in the process of proliferation and metastasis in breast neoplasm.
Wang X; Zou S
J Tongji Med Univ; 2001; 21(3):231-2. PubMed ID: 12539585
[TBL] [Abstract][Full Text] [Related]
6.
Chakraborty S; Ghosh S
Indian J Surg Oncol; 2024 May; 15(Suppl 2):226-231. PubMed ID: 38817999
[TBL] [Abstract][Full Text] [Related]
7. MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.
Walker AK; Karaszi K; Valentine H; Strauss VY; Choudhury A; McGill S; Wen K; Brown MD; Ramani V; Bhattarai S; Teo MTW; Yang L; Myers KA; Deshmukh N; Denley H; Browning L; Love SB; Iyer G; Clarke NW; Hall E; Huddart R; James ND; Hoskin PJ; West CML; Kiltie AE
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):809-818. PubMed ID: 30885775
[TBL] [Abstract][Full Text] [Related]
8. [The clinic and pathologic significance of plasma cell myeloma with CCND1].
Sun Q; An G; Liu E; Li Z; Zhang H; Yang Q; Sun F; Ma Y; Xian M; Zhang P; Ru K
Zhonghua Xue Ye Xue Za Zhi; 2015 Sep; 36(9):775-9. PubMed ID: 26462780
[TBL] [Abstract][Full Text] [Related]
9. Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma.
Wang B; Xie H; Ma C; Zhang G; Gan H; Wang Q; Liu X; Zhu Y; Zhu Y; Shi G; Zhang H; Dai B; Shen Y; Ye D
J Cancer; 2017; 8(17):3490-3497. PubMed ID: 29151933
[No Abstract] [Full Text] [Related]
10. Developing Precision Medicine for Bladder Cancer.
Guercio BJ; Iyer G; Rosenberg JE
Hematol Oncol Clin North Am; 2021 Jun; 35(3):633-653. PubMed ID: 33958155
[TBL] [Abstract][Full Text] [Related]
11. Current and Emerging Strategies to Treat Urothelial Carcinoma.
Rani B; Ignatz-Hoover JJ; Rana PS; Driscoll JJ
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835580
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of ZNF280A inhibits cell proliferation and promotes cell apoptosis of bladder cancer.
He L; Wang X; Chen P; Du C; Li J
Histol Histopathol; 2024 Mar; 39(3):367-379. PubMed ID: 37345848
[TBL] [Abstract][Full Text] [Related]
13. Systems Drug Design for Muscle Invasive Bladder Cancer and Advanced Bladder Cancer by Genome-Wide Microarray Data and Deep Learning Method with Drug Design Specifications.
Su PW; Chen BS
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430344
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors.
Jardim DLF; Millis SZ; Ross JS; Lippman S; Ali SM; Kurzrock R
Oncologist; 2023 Feb; 28(2):e82-e91. PubMed ID: 36082904
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 mediated by the nuclear translocation of nuclear factor kappa B exerts an oncogenic role in lung cancer.
Wang X; Liu X; Yang Y; Yang D
Bioengineered; 2022 Mar; 13(3):6866-6879. PubMed ID: 35246017
[TBL] [Abstract][Full Text] [Related]
16. Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study.
Al-Ezzi EM; Veitch ZW; Salah SH; Van der Kwast TH; Stockley TL; Selvarajah S; Zhang T; Sridhar SS; Sacher AG; Fallah-Rad N; Kulkarni GS; Zlotta AR; Finelli A; Hansen AR
PLoS One; 2021; 16(12):e0259272. PubMed ID: 34851968
[TBL] [Abstract][Full Text] [Related]
17. [
Liu DR; Liu Y; Wu PL; Zheng LL; Huang XY; Meng XH; Hu Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 May; 52(3):438-444. PubMed ID: 34018362
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of GINS4 Is Associated With Tumor Progression and Poor Survival in Hepatocellular Carcinoma.
Zhang Z; Chen P; Xie H; Cao P
Front Oncol; 2021; 11():654185. PubMed ID: 33842367
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy.
Wu J; Wen JM; Wang YC; Luo WJ; Wang QF; Lv H; Dai B; Ye DW; Su HC; Zhu YP
Front Oncol; 2021; 11():641385. PubMed ID: 33842349
[TBL] [Abstract][Full Text] [Related]
20. EPHA2 Promotes the Invasion and Migration of Human Tongue Squamous Cell Carcinoma Cal-27 Cells by Enhancing AKT/mTOR Signaling Pathway.
Wang F; Zhang H; Cheng Z
Biomed Res Int; 2021; 2021():4219690. PubMed ID: 33834064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
